CN Patent

CN105985227A — 4,4’-二卤乙酰联苯的制备及应用

Assigned to SHANGHAI TEHUA MEDICINE SCIENCE AND TECHNOLOGY Co Ltd · Expires 2016-10-05 · 10y expired

What this patent protects

本发明涉及4,4’-二卤乙酰联苯的制备方法及其在Daclatasvir中间体合成中的应用。本发明所述制备方法的原料如联苯和卤乙酰化试剂等均价廉易得；且通过4,4’-二卤乙酰联苯可“一锅法”合成Daclatasvir中间体，简化了工艺，大大提高了反应收率。

USPTO Abstract

本发明涉及4,4’-二卤乙酰联苯的制备方法及其在Daclatasvir中间体合成中的应用。本发明所述制备方法的原料如联苯和卤乙酰化试剂等均价廉易得；且通过4,4’-二卤乙酰联苯可“一锅法”合成Daclatasvir中间体，简化了工艺，大大提高了反应收率。

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN105985227A
Jurisdiction: CN
Classification: —
Expires: 2016-10-05
Drug substance claim: No
Drug product claim: No
Assignee: SHANGHAI TEHUA MEDICINE SCIENCE AND TECHNOLOGY Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.